What's too bad is that some of the scum have been
Post# of 72446
Posted On: 10/07/2015 4:17:45 PM
Re: daydreaming2 #14439
What's too bad is that some of the scum have been buying stock at the bargain prices, and will profit greatly when this goes back up to a fairer valuation.
Unbelievable that AVXL (80% of my position I still own, sold 20% the other day when it ran up big) has a higher market cap than CTIX -- unbelievable since AVXL has only one drug, and it's not as far along in clinical trials as Brilacidin. I am still cautiously bullish on AVXL -- if their Alzheimers/epilepsy drug works, it really WILL be worth 50/share or so, minimum -- but one drug in human trials in Australia, versus CTIX with 4 drugs in human trials in the U.S.? Gimme a break.
Of course the one that makes both these companies look sick is the scam AXON, announcing that it's going to take its previously failed Alzheimer's drug into a new Phase 3 trial -- with much lower endpoints for "success" than in its previous failed trial. THAT garbage stock has 5 times or so CTIX and AVXL's market cap -- and the likelihood of a meaningful success for AXON is small. Just shows, efficient market theory is a fraud and a lie, and having Wall Street insiders IPO'ing and then pumping your company is a much better financial strategy than just having promising drugs for life-threatening conditions. Bleah.
Unbelievable that AVXL (80% of my position I still own, sold 20% the other day when it ran up big) has a higher market cap than CTIX -- unbelievable since AVXL has only one drug, and it's not as far along in clinical trials as Brilacidin. I am still cautiously bullish on AVXL -- if their Alzheimers/epilepsy drug works, it really WILL be worth 50/share or so, minimum -- but one drug in human trials in Australia, versus CTIX with 4 drugs in human trials in the U.S.? Gimme a break.
Of course the one that makes both these companies look sick is the scam AXON, announcing that it's going to take its previously failed Alzheimer's drug into a new Phase 3 trial -- with much lower endpoints for "success" than in its previous failed trial. THAT garbage stock has 5 times or so CTIX and AVXL's market cap -- and the likelihood of a meaningful success for AXON is small. Just shows, efficient market theory is a fraud and a lie, and having Wall Street insiders IPO'ing and then pumping your company is a much better financial strategy than just having promising drugs for life-threatening conditions. Bleah.
(0)
(0)